Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Executive Summary
Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.
| Table |
|---|
Advertisement
Related Content
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
Another Strong Quarter For AbbVie, But How Long Will Good Times Last?
Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar
Humira Biosimilar Under Review: Amgen, AbbVie Tango Time
Amgen Biosimilars Game On: Filing Chases AbbVie's Humira
When It Comes To Biosimilar Marketing, Two Roads Diverge
Defender Or Opponent? Amgen Straddles The Biosimilar Line
Topics
- Subjects
- Approvals
- Biosimilars
- Commercial
- Policy & Regulation
- Companies
- Regions
- North America
- Industries
- BioPharmaceutical
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC097357
Ask The Analyst
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC097357
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.